Richard Brudnick - 19 Oct 2022 Form 3 Insider Report for Prime Medicine, Inc. (PRME)

Role
Chief Business Officer
Signature
/s/ Carman Alenson attorney-in-fact
Issuer symbol
PRME
Transactions as of
19 Oct 2022
Net transactions value
$0
Form type
3
Filing time
19 Oct 2022, 20:05:47 UTC
Previous filing
14 Oct 2022
Next filing
13 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRME Stock Option (right to buy) 19 Oct 2022 Common Stock 167,267 $7.96 Direct F1
holding PRME Stock Option (right to buy) 19 Oct 2022 Common Stock 19,300 $7.96 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date
F2 The shares underlying this option shall vest in full upon the successful completion of the Issuer's initial public offering.

Remarks:

Exhibit 24 - Power of Attorney